As of 2026-03-19, the Intrinsic Value of Summit Therapeutics Inc (SMMT) is -4.81 USD. This SMMT valuation is based on the model Peter Lynch Fair Value. With the current market price of 15.60 USD, the upside of Summit Therapeutics Inc is -130.84%.
Based on its market price of 15.60 USD and our intrinsic valuation, Summit Therapeutics Inc (SMMT) is overvalued by 130.84%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -4.81 - -4.81 | -4.81 | -130.84% |
| P/E | (18.03) - (20.88) | (20.06) | -228.6% |
| DDM - Stable | (5.36) - (18.36) | (11.86) | -176.0% |
| DDM - Multi | (0.42) - (1.21) | (0.63) | -104.1% |
| Market Cap (mil) | 12,095.77 |
| Beta | 1.39 |
| Outstanding shares (mil) | 775.37 |
| Enterprise Value (mil) | 11,870.51 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.64% |
| Cost of Debt | 5.00% |
| WACC | 8.16% |